Is TuHURA Biosciences, Inc. (HURA) a Buy, Sell, or Hold?
NASDAQ : HURA
TuHURA Biosciences, Inc.
$2.25 USD
$0.03 (1.35%)
- Volume
- 162.49K
- Average Volume
- 661.92K
- Market Capitalization
- $143.29M
- P/E Ratio
- -3.67
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.90
- Year Low
- $0.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.15
Company Overview
NASDAQ
James A. Bianco
Biotechnology
Healthcare
HURA
22
US
USD
Liquidity Metrics
0.02
1.15
1.15
1.04
0.00
Sales & Valuation
-$
0.00
5.82
-5.23
-0.46
Profitability
-$0.63
-$30.06M
0.00%
0.00%
-153.99%
-104.13%
P/E Metrics
-3.67
-0.03
-0.03
Analyst Price Target & Rating
2/5
2 Analysts
%
Poll Results
About TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida. ...
2026-06-15 07:45:00
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML) The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026 TAMPA, Fla., June 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers.
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-15 17:00:00
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-12 07:30:00
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A.
2026-04-22 07:30:00
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses.
Frequently Asked Questions
-
What is the current TuHURA Biosciences, Inc. (HURA) stock price?
-
TuHURA Biosciences, Inc.(NASDAQ:HURA) stock price is $2.25 in the last trading session. During the trading session, HURA stock reached the peak price of $3.9 while $0.41 was the lowest point it dropped to. The percentage change in HURA stock occurred in the recent session was 1.35% while the dollar amount for the price change in HURA stock was $0.03.
-
HURA's industry and sector of operation?
-
The NASDAQ listed HURA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HURA?
-
Dan Dearborn | Executive Vice President of Finance & Chief Financial Officer
Patricia Lawman | Co-Founder
Michael Lawman | Co-Founder
Michael Krsulich | Head of Quality Assurance
Bertrand Le Bourdonnec | Executive Vice President, Head of Drug Discovery, Early Development, & Program Management -
How many employees does HURA have?
-
Number of HURA employees currently stands at 22. HURA operates from 10500 University Center Drive, Tampa, FL None, US.
-
Link for HURA official website?
-
Official Website of HURA is: http://www.tuhurabio.com
-
How do I contact HURA?
-
HURA could be contacted at phone #+1 813 514 8373 and can also be accessed through its website. HURA operates from 10500 University Center Drive, Tampa, FL None, US.
-
How many shares of HURA are traded daily?
-
The average number of HURA shares traded daily for last 3 months was 661.92K.
-
What is the market cap of HURA currently?
-
The market value of HURA currently stands at $143.29M with its latest stock price at $2.25